SSY Group (02005) has announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for three products, all classified as Category 4 chemical drugs and deemed to have passed consistency evaluation.
The first product is Compound Tropicamide Eye Drops (0.4ml), primarily used for mydriasis and cycloplegia for diagnostic and therapeutic purposes. Compound tropicamide eye drops are a commonly used preparation for ophthalmic mydriasis and refractive examinations, featuring rapid onset, short duration of action, and clear clinical necessity. This product adopts a 0.4ml single-use packaging that is preservative-free, with dosage matching a single optometry session and less drug waste, making it more suitable for pediatric refractive screening scenarios, thereby enriching the group's ophthalmic medication product line.
The second product is Tofacitinib Citrate Extended-Release Tablets (11mg), primarily indicated for adult patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Tofacitinib is an oral small-molecule JAK inhibitor, with overall clinical efficacy comparable to TNF-alpha inhibitor biologics. Compared to biologics requiring regular injections, this product's extended-release formulation enables once-daily oral administration, greatly improving convenience and offering significant advantages in long-term medication adherence. The group has supporting in-house active pharmaceutical ingredient production capacity, forming an integrated API-plus-formulation layout with controllable costs and a stable supply chain. With outstanding product differentiation, it is highly suitable for rheumatology and immunology chronic disease management scenarios, and can focus on dual-channel and out-of-hospital retail marketing channels to achieve long-term steady penetration.
The third product is Sacubitril Valsartan Sodium Tablets (200mg), primarily used for adult patients with chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization. Sacubitril valsartan sodium tablets are a first-line medication recommended by heart failure and hypertension guidelines. This product combines blood pressure reduction with cardiovascular target organ protection, offering clear clinical benefits and further enriching and improving the group's product portfolio in the cardiovascular and cerebrovascular chronic disease sector.
Comments